41 results about "Carcinoma prostate" patented technology

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

The invention discloses a phosphorylated peptidomimetic compound and a medical application thereof. The invention provides a phosphorylated peptidomimetic compound with a novel structure. Activity research shows that the phosphorylated peptidomimetic compound has excellent Cbl-b inhibitory activity and is an effective Cbl-b inhibitor. Technicians in the field know that Cbl-b overexpression can inhibit T cell immune response, and inhibition of Cbl-b can activate killing of an immune system on tumor cells. Therefore, the phosphorylated peptidomimetic compound or pharmaceutically acceptable salts and solvates thereof provided by the invention can be developed and prepared into drugs for treating diseases (such as non-small cell lung cancer, breast cancer, prostate cancer, head and neck squamous cell carcinoma, liver cancer, pancreatic cancer, colorectal cancer, ovarian cancer and other tumors) treated or relieved by inhibiting Cbl-b (such as non-small cell lung cancer, breast cancer, prostate cancer, head and neck squamous cell carcinoma, liver cancer, pancreatic cancer, colorectal cancer, ovarian cancer and the like) the medicine prospect is promising.

The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer associated with FBOX21 mediated p85a ubiquitination such as, for example, cancer (e.g., sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate RSK signaling. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin to inhibit RSK. Some aspects of the invention provide methods of using N-desmethyl ruboxistaurin in the treatment of subjects with cancer, including breast cancer, ovarian cancer, prostate cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, melanoma, osteosarcoma, myeloproliferative neoplasms, leukemia, and bladder cancer. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, inhibits RSK and shows a safety profile that supports its long-term use.

The application provides a prostate cancer biochemical recurrence prognosis risk prediction model based on fatty acid metabolism and cancer cell stemness genes and a construction method thereof, wherein the construction method comprises the following steps: S1: data collection: obtaining prostate cancer sample transcriptome data with biochemical recurrence information from a database, and dividing the data into a model training set and a model test set; S2: stemness score analysis; S3: fatty acid metabolism score analysis; S4: based on the analysis results of S2 and S3, identifying a co-expression gene module related to fatty acid metabolism and stemness characteristics in prostate cancer by a co-expression similarity algorithm and a hierarchical clustering algorithm, and obtaining a fatty acid metabolism and stemness-related gene set; S5: constructing a prostate cancer BCR prognosis risk prediction model; S6: constructing a nomogram model; S7: extracting RNA of a to-be-tested sample, constructing a cDNA library, quantifying the expression of the above genes, and calculating the prognosis risk level of prostate cancer through the expression level.

The application discloses application of a reagent for detecting AHSP protein in preparation of a product for diagnosing prostate cancer, and relates to the technical field of biological medicine; through proteomic analysis, ELISA test on urine protein of prostate cancer patients, clear cell renal cell carcinoma patients and normal healthy men, and immunohistochemical analysis on file wax blocks of the prostate cancer patients, normal prostate tissues around the cancer, prostate tissues of prostatic hyperplasia and clear cell renal cell carcinoma tissues, it is found that the AHSP protein has a certain relationship with the occurrence and development of prostate cancer, and can be used for assisting diagnosis of the prostate cancer; and in urine detection, AHSP has higher sensitivity than PSA, and when PSA is negative or serum PSA is low, AHSP can form complementation with ASHP, thereby helping to improve the diagnosis rate and non-invasive screening ability; through research on the relationship between the AHSP protein and the prostate cancer, the diagnosis rate of patients can be improved, non-invasive reexamination after treatment is facilitated, drug use is guided, and the survival rate is improved.

Disclosed are methods for detecting and treating cancers (such as carcinoma, leukemia, lung cancer, colon cancer, central nervous system (CNS) cancer, melanoma, ovarian cancer, renal cancer, oral cancer, prostate cancer and / or breast cancer). The method may include receiving a sample from a patient (such as a sample from a biopsy, a sample from an extracellular vesicle, or a sample from a circulating tumor cell). The method may include determining whether a LY6C protein or a phosphorylated ANXA2 protein is detected in the sample. The method may include treating a patient for cancer by targeting the LY6C protein when the LY6C protein is detected (e.g., using photoimmunotherapy (PIT) or near infrared photoimmunotherapy (NIR-PIT)). or treating a patient for cancer by targeting an ANXA2 protein (e.g, using inhibitors, decoys, etc.) when the phosphorylated ANXA2 protein is detected.

This invention discloses a robotic multi-needle puncture trajectory planning method for prostate cancer. By acquiring two-dimensional ultrasound images and spatial positioning data of the prostate, the coordinates of three-dimensional feature points of obstacles such as blood vessels and the pubic bone are obtained. The tumor contour is extracted using a combination of manual delineation and an improved target detection algorithm to complete three-dimensional reconstruction of the prostate and tumor, as well as implicit function modeling of obstacles, constructing a personalized three-dimensional surgical environment. This method employs a progressive planning strategy, solving for a collision-free reachable workspace for each needle, optimizing the needle insertion trajectory with the shortest path and minimal trauma as objectives, and establishing a tissue deformation compensation model to correct target point offset. Simultaneously, the implanted puncture needles are used as dynamic obstacle iterative update constraints to achieve cyclical optimization of the multi-needle trajectory. Finally, a six-degree-of-freedom robotic arm equipped with a needle guide device completes precise positioning and puncture assistance, achieving orderly, collision-free multi-needle implantation. This invention effectively improves puncture positioning accuracy and surgical safety, reduces manual intervention, and provides an automated, high-precision trajectory planning solution for prostate particle implantation.

Provided are compositions and methods that include use of micro-RNAs and mimics of the micro-RNAs for treating cancer. Specific ratios of micro-RNAs that have enhanced anti-cancer properties for treating prostate, bladder, and head and neck cancer are provided. The micro-RNAs are conjugated to nanoparticles configured so that exposure to light releases the micro-RNAs from the nanoparticles, thereby allowing the microRNAs to elicit anti-cancer effects.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly ovarian cancer, gastrointestinal cancer, pancreatic cancer, prostate cancer, stromal cancer, osteosarcoma, colon cancer, breast cancer, skin cancer, melanoma, esophageal cancer, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESSC), particularly esophageal cancer, or EAC or ESSC.

The invention discloses a preparation method and application of a prostate cancer tissue single-cell suspension. The preparation method of the prostate cancer tissue single-cell suspension comprises the following steps: S1, tissue pretreatment: putting a prostate cancer tissue sample into a low-temperature pretreatment buffer solution, and cutting the prostate cancer tissue sample into tissue fragments; s2, circular enzymolysis: mixing the tissue fragments with a composite enzymatic hydrolysate, and performing digestion for multiple rounds under an oscillation condition; after each round of digestion, collecting supernate into a stop solution containing serum, repeatedly digesting the remaining tissues for multiple times, and combining the supernate to obtain a cell crude suspension; wherein the composite enzymatic hydrolysate contains collagenase, protease, nuclease, an androgen receptor stimulant and / or a ROCK inhibitor; and S3, sequentially carrying out separation and purification on the cell crude suspension through filtration and density gradient centrifugation to obtain the prostate cancer tissue single-cell suspension.

The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and / or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS.

This application discloses the application of PLAC8 as a target in the preparation of tumor therapeutic drugs, involving the field of biomedical technology. This application clarifies that the "sympathetic nervous system-β2-AR-PLAC8-cholesterol metabolism-M2 polarization" pathway is the core driving pathway for stress-related tumor progression and chemotherapy resistance. It reveals the molecular mechanism by which PLAC8 inhibits cholesterol synthesis through phosphorylation at the S67 site, binding to the N-terminal domain of SREBP2, recruiting OGT to mediate SREBP2O-GlcNAc glycosylation. Through strategies such as gene silencing, β2-AR antagonist intervention, and targeted delivery of siPLAC8 via mannose-modified lipid nanoparticles (LNPs), the application achieved the effects of inhibiting M2 macrophage accumulation, inhibiting tumor growth, and reversing chemotherapy resistance in various tumor models, including gallbladder cancer, intrahepatic cholangiocarcinoma, and prostate cancer. Furthermore, the LNPs delivery system showed no significant toxicity. This research provides a novel therapeutic target centered on PLAC8 and a safe and effective targeted intervention strategy for stress-related tumors, highlighting its clinical translational value.

The application provides a novel DNA methylation marker TAGMe-5 for tumor identification and use thereof. The tumor marker TAGMe-5 of the application shows significant DNA methylation difference between cancer adjacent tissue and cancer tissue, and the difference has significant statistical significance, and the difference is shown in numerous tumors such as solid tumors and non-solid tumors. The solid tumors include lung cancer, liver cancer, prostate cancer, cervical cancer, endometrial cancer, urothelial carcinoma, biliary tract tumor, etc. The non-solid tumors include hematological tumors, lymphoma, etc. Therefore, the tumor marker of the application can be used for clinical screening of pan-cancer, molecular diagnosis, prognosis and efficacy evaluation.

A kind of auxiliary identification method for bladder neck disconnection of minimally invasive prostate cancer radical surgery, it is related to image recognition field, including obtaining video stream from endoscope, and carrying out pretreatment;Extract the multi-scale feature of real-time image in the video stream after pretreatment, generate multi-scale feature map;Position coding and deep feature extraction are carried out based on multi-scale feature map, obtain global feature map;Global feature map is mapped as the control point of Bezier curve, then a smooth cutting line is fitted;Global feature map and control point are processed, generate Gaussian heat map, output the probability distribution of the best cutting line and the farthest cutting line of bladder neck, and the segmentation result of prostate and bladder;It is used to solve the problems that traditional method is difficult to identify the best disconnection position of bladder neck, and cannot provide clear cutting line guidance.

Disclosed are methods for detecting and treating cancers (such as carcinoma, leukemia, lung cancer, colon cancer, central nervous system (CNS) cancer, melanoma, ovarian cancer, renal cancer, oral cancer, prostate cancer and / or breast cancer). The method may include receiving a sample from a patient (such as a sample from a biopsy, a sample from an extracellular vesicle, or a sample from a circulating tumor cell). The method may include determining whether a LY6C protein or a phosphorylated ANXA2 protein is detected in the sample. The method may include treating a patient for cancer by targeting the LY6C protein when the LY6C protein is detected (e.g., using photoimmunotherapy (PIT) or near infrared photoimmunotherapy (NIR-PIT)). or treating a patient for cancer by targeting an ANXA2 protein (e.g, using inhibitors, decoys, etc.) when the phosphorylated ANXA2 protein is detected.

The invention provides application of an EGFR (epidermal growth factor receptor) inhibitor in preparation of a medicine for treating diseases mediated by the activity of a guanylate exchange factor (GEF) or jointly mediated by the activity of the guanylate exchange factor (GEF) and the activity of EGFR tyrosine kinase. The diseases are cancers selected from the following groups: lung cancer, colon cancer, breast cancer, endometrial cancer, thyroid cancer, glioma, squamous cell carcinoma, prostate cancer, melanoma, leukemia and glioblastoma. Specifically, the invention discovers that EGFR has a GEF function for promoting activation of Ras homologous protein (Rhb) besides traditional tyrosine kinase activity, the function does not depend on the tyrosine kinase activity and plays a key role by depending on a glutamic acid residue at the 804th site on an EGFR molecule, the Rhb-GEF activity of EGFR causes allosteric activation of a mammal rapamycin target protein complex 1 (mTORC1), and the activity of the EGFR causes allosteric activation of the mammal rapamycin target protein complex 1 (mTORC1). The tumor growth is finally promoted.

The present invention provides a gender-neutral, non-invasive diagnostic method for detecting urological cancers, including prostate, bladder, kidney, renal pelvis, and testis cancers, using urine-based microRNA (miRNA) biomarkers. The method comprises obtaining a self-collected urine sample, extracting miRNA, and quantifying biomarker expression levels using, e.g., reverse transcription quantitative PCR (RT-qPCR), next-generation sequencing (NGS), or microarray analysis. A panel of miRNAs, e.g., hsa-let-7b-5p, hsa-miR-26b-5p, hsa-miR-145-5p, hsa-miR-4253p, hsa-miR-195-5p, hsa-miR-203a-3p, hsa-miR-30c-5p, and hsa-miR-30a-3p, enables sensitive and specific discrimination between cancer and non-cancer patients. The invention is capable of high diagnostic performance and accuracy. The assay may be highly reproducible. This present invention provides a cost-effective, non-invasive, inclusive platform applicable across cisgender, transgender, and non-binary populations, facilitating early cancer detection and improved healthcare accessibility.

The present invention discloses a PSMA-targeted radiometal complex containing a nitroaromatic heterocyclic group and its preparation, which belongs to the technical fields of radiopharmaceuticals and medical imaging. The general formula of the PSMA-targeted radiometal complex containing a nitroaromatic heterocyclic group of the present invention is shown in Formula I and Formula II. The present invention is the first to link both a nitroaromatic group and a PSMA-targeting group to a metal chelator (such as HBED-CC, DOTA, DOTA(GA)2, NOTA, AAZTA, etc.) and to target a radiometal nuclide, e.g. 68 Ga, 18 F-AlF, 177 Lu, 90 Y, 44 Sc, 225 Ac, 212 Pb, 213 The radioactive metal marker is labeled with Bi, etc. The synergistic effect of the nitroaromatic heterocyclic group in vivo is expected to increase the uptake of the radioactive metal marker by prostate cancer, promoting metabolism in non-target organs and improving the therapeutic efficacy of radiopharmaceuticals against tumors. JPEG2026508753000106.jpg2835JPEG2026508753000107.jpg2145 (wherein the R1 and R2 groups are nitroaromatic heterocyclic groups; L2 is a linking group between the R1 group and L1, where L1 is a linking group between the chelator and the structure PSMA targeting structure; L4 is a linking group between the R2 group and L3, where L3 is a linking group between the chelator and the structure PSMA targeting structure; and ChelatoR1 and ChelatoR2 are chelators or chelating structures.)

Disclosed herein are crystalline polymorphs of LMP744 that can be used in the treatment of cancers associated with dysregulation of Top1 and / or MYC activity, such as, for example, a sarcoma, (e.g., Ewing's sarcoma), a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, non-small cell lung carcinoma, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, a melanoma, a glioma, leukemia, a lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, and plasma cell neoplasm (myeloma). This abstract is intended as a scanning tool for purposes of searching m the particular art and is not intended to be limiting of the present invention.

The invention discloses a visual paper-based cancer miRNA marker detection kit, the kit comprises an integrally formed foldable T-shaped filter paper, and a DNA probe TEprobe, urease and a color developing agent dropwise added on the filter paper, and the principle of the kit is as follows: the TEprobe is combined with a cancer nucleic acid marker (miRNA) to release Ag < + > to inhibit the activity of the urease; the composite signal response of the pH response probe phenol red and fluorescein is triggered, and the detection sensitivity is as low as 10-12 M. The kit provided by the invention can significantly shorten the detection time and reduce the sample demand, and realizes zero false positive rate and 97.10% specificity by combining with machine learning algorithm classification during result analysis. The performance is successfully verified in real samples of prostatic cancer, liver cancer and colorectal cancer, and a cheap and convenient means is expected to be provided for family self-inspection and cancer screening and diagnosis in resource-deficient areas.

This invention discloses the application of a biomarker in assessing the risk of prostate cancer recurrence, belonging to the field of tumor molecular diagnostics and bioinformatics technology. The biomarker includes at least one of the TACR2 and LPIN3 genes, and RCCD1, PRSS27, and NAP1L5, with the core detection focusing on the methylation-transcriptional combined characteristics of the TACR2 gene. This invention obtains patient samples, uses RT-qPCR to detect the expression levels of multiple genes, and methylation-specific PCR to detect the methylation level of the TACR2 promoter region. A risk scoring model is constructed using LASSO regression, and patient prognosis is stratified based on the score. This invention solves the problems of traditional assessment indicators being affected by tumor heterogeneity and having limited predictive accuracy. It is the first to use TACR2-related multi-omics characteristics for prostate cancer recurrence assessment. The multi-gene combined model improves predictive accuracy and can be developed into a standardized testing kit, providing a scientific basis for clinical recurrence risk assessment and personalized treatment, with significant industrial and clinical application value.

The present invention provides a gender-neutral, non-invasive diagnostic method for detecting urological cancers, including prostate, bladder, kidney, renal pelvis, and testis cancers, using urine-based microRNA (miRNA) biomarkers. The method comprises obtaining a self-collected urine sample, extracting miRNA, and quantifying biomarker expression levels using, e.g., reverse transcription quantitative PCR (RT-qPCR), next-generation sequencing (NGS), or microarray analysis. A panel of miRNAs, e.g., hsa-let-7b-5p, hsa-miR-26b-5p, hsa-miR-145-5p, hsa-miR-4253p, hsa-miR-195-5p, hsa-miR-203a-3p, hsa-miR-30c-5p, and hsa-miR-30a-3p, enables sensitive and specific discrimination between cancer and non-cancer patients. The invention is capable of high diagnostic performance and accuracy. The assay may be highly reproducible. This present invention provides a cost-effective, non-invasive, inclusive platform applicable across cisgender, transgender, and non-binary populations, facilitating early cancer detection and improved healthcare accessibility.

The invention discloses application of parabacteroides dieldrii in preparation of a medicine for treating prostatic cancer, and belongs to the field of biological medicine. It is found for the first time that the abundance of parabacteroides dieldrii in intestinal flora of a prostate cancer patient is remarkably reduced, and the parabacteroides dieldrii is selected as potential probiotics for inhibiting growth of prostate cancer tumors. The result of a parabacteroides dieldrii single bacterium colonization experiment shows that the parabacteroides dieldrii and the metabolite gamma-linolenic acid (GLA) thereof can efficiently inhibit the growth of the prostatic cancer tumor, can also improve the condition that the treatment effect of docetaxel on the prostatic cancer is poor due to abuse of clinical antibiotics, and can be prepared into the medicine for treating or assisting in treating the prostatic cancer. The invention provides a new treatment strategy and medicine for the treatment of the prostatic cancer, and also provides a brand new medicine development path and a clinical application scheme for the micro-ecological treatment of the prostatic cancer.

PI3Kδ implicates hematologic cancers and solid tumors. Alternative splicing is a post-transcriptional process for acquiring proteomic diversity in eukaryotic cells. Emerging evidence highlights the involvement of aberrant mRNA splicing in cancer development / progression. PI3Kδ-L and PI3Kδ-S are overexpressed in advanced solid tumors, such as prostate, breast, colon, lung and pancreatic cancers. Differential PI3Kδ and PI3Kδ-S expression profiles were identified in a panel of solid tumor cells. PI3Kδ inhibitor Idelalisib and SRPK1 / 2 inhibitor SRPIN340 were employed to assess their efficacies on inhibiting the PI3Kδ-expressing solid tumors. Idelalisib effectively inhibits PI3Kδ-L and its downstream signaling. Idelalisib fails to inhibit PI3Kδ-S activity and its downstream signaling. SRPIN340 reverses the aberrant mRNA splicing, thereby inhibiting the downstream AKT / mTOR signaling. In vitro functional assays further demonstrate that a combination of Idelalisib and SRPIN340 achieve a synergistic drug effect, with drastically reduced cell viabilities / growths of tumor spheroids, in inhibiting the advanced tumor cells.

Pharmaceutical compositions and methods for using boron-based ligands of enolases to treat cancer are disclosed. One such pharmaceutical composition includes a therapeutically effective amount of a ligand of enolase (1) having a general formula III or a pharmaceutically acceptable derivative thereof. The cancer can be a carcinoma, sarcoma, lymphoma, leukemia, or melanoma. The cancer can be prostate cancer.

The present invention provides a compound of Formula I, a salt thereof, or a solvate thereof, as described herein, the composition is used for treating MYC positive cancers including lung cancer, leukemia, breast cancer, myeloproliferative diseases, colorectal cancer, medulloblastoma, kidney cancer, hepatocellular cancer, melanoma, ovarian cancer, prostate cancer, esophageal adenocarcinoma, liposarcoma, esophageal squamous carcinoma, gastrointestinal stromal tumor, glioma, mucus fibrosarcoma, smooth muscle sarcoma, neuroblastoma, synovial sarcoma, mesothelioma, and the like. Gastric cancer, thyroid cancer, lymphoma, osteosarcoma, rhabdomyosarcoma, fibrosarcoma, epithelial cancer and neurological cancer.

The present application relates to cancer, and particularly to the application of circPIAS1-108aa and its inhibitor in the preparation of antitumor drugs. The application of circPIAS1-108aa as a target in the development or screening or preparation of drugs for preventing or treating tumors is characterized in that the amino acid sequence of the circPIAS1-108aa is SEQ ID NO. 1. The present application finds the application of the inhibitor of the target circPIAS1-108aa in the treatment of cancer through experiments. The inhibitor plays a role in inhibiting proliferation in ten common cancers, including lung cancer, liver cancer, gastric cancer, melanoma, pancreatic cancer, breast cancer, nasopharyngeal carcinoma, colorectal cancer, esophageal cancer and prostate cancer; and the inhibitor of the target circPIAS1-108aa can significantly enhance the efficacy of immune checkpoint inhibitors, providing a new synergistic strategy for tumor immunotherapy.

The present application relates to the technical field of drug synthesis, in particular to a benzylurea compound, a preparation method and application thereof. The structural formula of the benzylurea compound is shown in the following: wherein R1 represents any one of a connecting bond, a substituted or unsubstituted amide bond and a C1-C10 unsubstituted alkyl bond, and R2 is selected from any one of a substituted or unsubstituted single aromatic heterocyclic group, or a substituted or unsubstituted single aromatic ring group, or a substituted or unsubstituted benzo-fused ring group. The benzylurea compound can effectively inhibit the activity of tumor cells, and has a good therapeutic effect on esophageal cancer, lung cancer, gastric cancer, breast cancer, colorectal cancer, laryngeal cancer, nasopharyngeal cancer, oral cancer, pancreatic cancer, renal cancer, prostate cancer, bladder cancer, cervical cancer, lymphoma, acute leukemia, osteosarcoma, Ewing's sarcoma and thyroid cancer.

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate CDK4 / 6 signaling. The invention encompasses methods for administering N-desmethyl ruboxistaurin to subjects in need, particularly those with a history of cancer or currently experiencing breast cancer, liposarcoma, lung cancer, glioblastoma, melanoma, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, colorectal cancer, bladder cancer, hepatocellular carcinoma, osteosarcoma, germ cell tumors, advanced solid tumors, lymphoma, leukemia and other hematologic malignancies. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, is effective in modulating CDK4 / 6 signaling while mitigating toxicity associated with other treatments.